Alnylam Pharmaceuticals Inc. gained additional government funding for its biodefense program with a $38.6 million grant from the U.S. Defense Threat Reduction Agency (DTRA) for the development of an RNAi drug to treat viral hemorrhagic fevers. (BioWorld Today)

Alnylam Pharmaceuticals Inc. gained additional government funding for its biodefense program with a $38.6 million grant from the U.S. Defense Threat Reduction Agency (DTRA) for the development of an RNAi drug to treat viral hemorrhagic fevers. (BioWorld Today)